Xilio Therapeutics Reports Q2 2026 Results, FDA Clears IND for XTX501, and Extends Cash Runway into Q1 2028

summarizeSummary

Xilio Therapeutics posted Q2 2026 results featuring $136.0M in cash and a reduced net loss, while securing FDA clearance of its IND for XTX501, a bispecific PD-1/masked IL-2. Cash runway extends into Q1 2028.

check_boxKey Events · Earnings and Guidance · XLO

• FDA Clears IND for XTX501

  The FDA cleared the investigational new drug application for XTX501, a bispecific PD-1/masked IL-2, enabling Xilio to begin dosing in a Phase 1/2 trial during the second half of 2026.

• Q2 2026 Financial Results

  As of June 30, 2026, cash and equivalents stood at $136.0 million. Collaboration revenue climbed to $18.7 million from $8.1 million a year earlier, while the net loss contracted to $6.4 million from $15.8 million.

• Cash Runway Extended into Q1 2028

  Current cash is expected to fund operations into the first quarter of 2028, excluding up to $36.2 million in potential warrant proceeds and up to $31.0 million in near-term milestones from AbbVie.

• Pipeline Milestones Ahead

  Looking forward, IND submissions for masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1 are anticipated in the second half of 2027, with initial Phase 1 data for XTX501 also expected in that period.

auto_awesomeAnalysis · XLO · Life Sciences

A pivotal regulatory step—FDA clearance of the IND for XTX501, a bispecific PD-1/masked IL-2—headlines Xilio Therapeutics' Q2 2026 update. The financial picture strengthened with $136.0 million in cash, collaboration revenue of $18.7 million fueled by AbbVie and Gilead partnerships, and a net loss that narrowed to $6.4 million. With runway now projected into Q1 2028, the company is well-positioned to advance its masked T cell engager pipeline. For a clinical-stage biotech, the IND clearance and upcoming first-in-human dosing later this year mark material progress.